Eterna Therapeutics INC

Ernexsa Therapeutics Inc. has released an updated investor presentation on July 2, 2026, providing new information and updates.

Ernexa Therapeutics Inc. reported the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Ernexa Therapeutics Inc. announced the resignation of Senior Vice President of Finance Sandra Gurrola, effective July 3, 2026.

Ernexia Therapeutics Inc. has filed a Form 8-K announcing a 1-for-25 reverse stock split of its common stock, effective May 4, 2026.

Ernexa Therapeutics Inc. received a Nasdaq delisting notice for failing to maintain a minimum bid price, complicated by a prior reverse stock split.

Ernexa Therapeutics Inc. announced the availability of an updated investor presentation, replacing a previous version from December 2025.

Ernexia Therapeutics reports increased R&D expenses and a significant goodwill impairment in Q1 2026, alongside progress in financing and Nasdaq compliance efforts.

Ernexa Therapeutics Inc. reported a reduced net loss for Q3 2025, driven by cost efficiencies and a recent $7.2 million capital raise, but faces substantial doubt about its ability to continue as a going concern.

Ernexa Therapeutics Inc. reported a reduced net loss and lower cash burn in Q2 2025, bolstered by a $7.2 million private placement, but faces substantial doubt about its ability to continue as a going concern.

Ernexa Therapeutics reports a net loss of $8.2 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while also announcing a new securities purchase agreement.

Eterna Therapeutics reports a net loss of $38.8 million for the nine months ended September 30, 2024, but completes a significant debt restructuring and regains compliance with Nasdaq listing requirements.

Eterna Therapeutics reported a net loss of $5.5 million for the second quarter of 2024 and faces substantial doubt about its ability to continue as a going concern due to insufficient cash reserves.

Ernexa Therapeutics Inc. reported significant losses and a going concern warning in its 2025 annual report, despite recent capital raises and progress in its preclinical cell therapy programs.

Eterna Therapeutics' 2024 10-K filing reveals significant losses, a going concern warning, and strategic shifts in their iMSC therapy development.

Eterna Therapeutics filed an amendment to its annual report to correct a typographical error in the date of the independent accounting firm's consent.

Eterna Therapeutics details its stock option and incentive plans, including terms for vesting, exercise, and tax implications, in a recent SEC filing.

Sandra M. Gurrola, Senior VP of Finance at Ernexa Therapeutics Inc., converted 30 restricted stock units into common stock on June 21, 2025, increasing her direct beneficial ownership of common stock to 110 shares.

Charles Cherington, a Director and 10% owner of Ernexa Therapeutics Inc. (ERNA), has substantially increased his beneficial ownership through a private placement and a stock dividend, now holding over 41 million shares.

Charles Cherington, a director and 10% owner of Ernexa Therapeutics, filed an amended Form 4 to correct the transaction date for the exchange of warrants and convertible notes to September 24, 2024, due to the execution of support agreements that practically assured stockholder approval.

Charles Cherington, a director and 10% owner of Eterna Therapeutics Inc., acquired 3,768,397 shares of common stock through a private placement on April 2, 2025.

Director William Wexler reports acquisition of stock options in Eterna Therapeutics.

Sandra M. Gurrola, Sr. VP of Finance at Eterna Therapeutics Inc., reports the acquisition of stock options.

Ernexa Therapeutics Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for July 1, 2026, to elect directors, ratify auditors, and approve an equity incentive plan.

Ernexa Therapeutics aims to regain Nasdaq compliance and enhance stock appeal through a reverse stock split, while also seeking approval for increased authorized shares and a securities purchase agreement.

Eterna Therapeutics is asking stockholders to vote on the election of directors, ratification of auditors, and a stock issuance proposal at its annual meeting on October 29, 2024.

Preclinical-stage biotech Ernexa Therapeutics Inc. is offering up to 13.59 million shares and accompanying warrants to raise an estimated $11.5 million for product development and working capital.

Ernexa Therapeutics Inc., a preclinical-stage cell therapy company, is offering up to $12.5 million in common stock and warrants to fund operations, despite significant accumulated losses and substantial doubt about its ability to continue as a going concern.

Eterna Therapeutics has filed a registration statement for the potential resale of up to 49,870,566 shares of its common stock by selling stockholders.

Charles Cherington has significantly increased his beneficial ownership in Ernexa Therapeutics Inc. to 37.9% of outstanding common stock through participation in a private placement and a dividend payment.

Charles Cherington has significantly increased his beneficial ownership in Ernexa Therapeutics Inc. to 32.8% through participation in a two-tranche private placement totaling approximately $7.25 million.

Charles Cherington, a significant investor, has increased his beneficial ownership in Eterna Therapeutics Inc. to 32.38% through a series of strategic debt and warrant conversions and exchanges.

Clear Street LLC has filed an amendment to its Schedule 13G to terminate its reporting obligation for Ernexa Therapeutics Inc. as its beneficial ownership has fallen below the 5% threshold.

Freebird Partners LP and affiliates have filed an amended Schedule 13G reporting a 9.9% beneficial ownership stake in Ernexa Therapeutics Inc.

John and Katherine Halpern have filed an amended Schedule 13G reporting a 5.6% beneficial ownership stake in Ernexa Therapeutics Inc.

Bleichroeder LP and Andrew Gundlach have filed a Schedule 13G reporting a 6.86% beneficial ownership stake in Ernexa Therapeutics Inc.

Clear Street LLC has reported beneficial ownership of 149,499 shares, representing 12.8% of the outstanding common stock of Ernexa Therapeutics Inc.

Shameek and Victoria Konar, through Regolith Capital Investments, have reported a 9.7% beneficial ownership in Ernexa Therapeutics following significant share consolidations.